{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:29:34Z","timestamp":1787837374290,"version":"build-2784847793"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Despite the increasing interest in radiogenomic prediction, few studies have directly compared the performance of logistic regression and decision tree models in distinguishing epidermal growth factor receptor (EGFR) mutation subtypes. This study provides the first systematic comparison of the predictive performance of these two models in identifying exon 19 deletions (19Del) and exon 21 L858R point mutations (21L858R) in patients with lung adenocarcinoma. By leveraging imaging and clinical parameters, we aimed to address a critical gap in the literature by establishing an optimal prediction model and providing a noninvasive tool to support personalized treatment strategies for patients with unknown EGFR mutation status.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We retrospectively collected clinical and radiological data from 193 patients with histologically confirmed lung adenocarcinoma who were admitted to the Second Affiliated Hospital of Anhui Medical University between May 2018 and June 2024. Based on EGFR genotyping results, patients were stratified into two groups: the EGFR 19Del mutation group and the EGFR 21L858R mutation group. Comparative statistical analyses\u2014including Student\u2019s <jats:italic>t<\/jats:italic>-test, Mann\u2013Whitney <jats:italic>U<\/jats:italic> test, chi-square test, or Fisher\u2019s exact test\u2014were performed to evaluate differences in clinical and CT imaging characteristics between groups. Variables with P &amp;lt; 0.05 in the univariate analysis were subsequently included in both logistic regression and decision tree models to identify independent predictors of EGFR mutation subtype. Model performance was assessed using ROC curve analysis. The area under the curve (AUC) was calculated for each model, and their predictive accuracy was further compared using DeLong\u2019s test, net reclassification improvement (NRI), and integrated discrimination improvement (IDI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the decision tree model, age and brain metastasis emerged as key decision nodes for differentiating 19Del and 21L858R mutations, with an AUC of 0.712 (95% CI: 0.639\u20130.785). In contrast, the logistic regression model identified age, pleural thickening, lymphadenopathy, and brain metastasis as independent predictors, achieving a higher AUC of 0.740 (95% CI: 0.671\u20130.810). The NRI and IDI values were 0.498 (<jats:italic>P<\/jats:italic> &amp;lt; 0.001, 95% CI: 0.238\u20130.758) and 0.043 (<jats:italic>P<\/jats:italic> = 0.004, 95% CI: 0.013\u20130.072), respectively, suggesting improved reclassification and discrimination by the logistic model. However, DeLong\u2019s test revealed no statistically significant difference between the AUCs of the two models (Z = 1.314, <jats:italic>P<\/jats:italic> = 0.189).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Both logistic regression and decision tree models demonstrated value in predicting EGFR 19Del and 21L858R mutations in lung adenocarcinoma, each offering distinct methodological advantages. The logistic regression model exhibited higher interpretability and statistical robustness, making it well-suited for clinical decision-making. Meanwhile, the decision tree model offered superior visual clarity and intuitive structure, which may enhance practical utility. A combined modeling approach that harnesses the strengths of both methods may provide a more accurate and comprehensive tool for early mutation identification and individualized treatment planning in patients with lung adenocarcinoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1642253","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:55Z","timestamp":1758168775000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Noninvasive prediction of EGFR 19Del and 21L858R subtypes in lung adenocarcinoma: a comparative study of logistic regression and decision tree models"],"prefix":"10.3389","volume":"15","author":[{"given":"Peng","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengYu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunHong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"20934","DOI":"10.1038\/s41598-024-71954-7","article-title":"Significance of novel PANoptosis genes to predict prognosis and therapy effect in the lung adenocarcinoma","volume":"14","author":"Miao","year":"2024","journal-title":"Sci Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061604","article-title":"The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies","volume":"15","author":"Laface","year":"2023","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3952-7","article-title":"Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer","volume":"18","author":"Kaneda","year":"2018","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12723","article-title":"Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3","volume":"106","author":"Kato","year":"2015","journal-title":"Cancer Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S313056","article-title":"Efficacy and safety of first-generation EGFR-TKIs combined with chemotherapy for treatment-na\u00efve advanced non-small-cell lung cancer patients harboring sensitive EGFR mutations: A single-center, open-label, single-arm, phase II clinical trial","volume":"14","author":"Lin","year":"2021","journal-title":"J Inflammation Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13577","article-title":"Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution","volume":"11","author":"Li","year":"2020","journal-title":"Thorac Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.014","article-title":"Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer","volume":"12","author":"Castellanos","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.846589","article-title":"Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma","volume":"12","author":"Huo","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1800986","DOI":"10.1183\/13993003.00986-2018","article-title":"Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.951575","article-title":"Deep learning analysis to predict EGFR mutation status in lung adenocarcinoma manifesting as pure ground-glass opacity nodules on CT","volume":"12","author":"Yoon","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.598721","article-title":"Deep CNN model using CT radiomics feature mapping recognizes EGFR gene mutation status of lung adenocarcinoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.675877","article-title":"Development and validation of a combined model for preoperative prediction of lymph node metastasis in peripheral lung adenocarcinoma","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s12149-022-01718-8","article-title":"Predictive value of multiple metabolic and heterogeneity parameters of (18)F-FDG PET\/CT for EGFR mutations in non-small cell lung cancer","volume":"36","author":"Shi","year":"2022","journal-title":"Ann Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2024.02.001","article-title":"A retrospective real-world study of prognostic factors associated with EGFR mutated lung cancer with leptomeningeal metastasis","volume":"25","author":"Wu","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e7208","DOI":"10.1002\/cam4.7208","article-title":"Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study","volume":"13","author":"Liang","year":"2024","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12996","article-title":"Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy","volume":"107","author":"Kobayashi","year":"2016","journal-title":"Cancer Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000519847","article-title":"Efficacy of icotinib, an EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients with exon 19 deletion and exon 21 L858R: A retrospective analysis in China","volume":"106","author":"Wang","year":"2021","journal-title":"Pharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2024_230616N316","article-title":"Silencing of lncRNA LOC105376794 promotes migration, invasion, and Gefitinib resistance of lung adenocarcinoma cells with EGFR 19Del mutation by ATF4\/CHOP axis and ERK phosphorylation","volume":"71","author":"Liu","year":"2024","journal-title":"Neoplasma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-507","article-title":"Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study","volume":"14","author":"Qian","year":"2022","journal-title":"J Thorac Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1177\/1724600820967015","article-title":"Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases","volume":"35","author":"Hu","year":"2020","journal-title":"Int J Biol Markers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2024.108258","article-title":"Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases","volume":"240","author":"Xu","year":"2024","journal-title":"Clin Neurol Neurosurg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/s41747-023-00396-z","article-title":"A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer","volume":"8","author":"Li","year":"2024","journal-title":"Eur Radiol Exp"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1949","DOI":"10.1097\/MD.0000000000001949","article-title":"The difference of clinical characteristics between patients with exon 19 deletion and those with L858R mutation in nonsmall cell lung cancer","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e34184","DOI":"10.1097\/MD.0000000000034184","article-title":"Clinical characteristics and establishment of a 2-year-OS predictive model of EGFR mutation-positive patients with pleural invasion of lung adenocarcinoma","volume":"102","author":"Kong","year":"2023","journal-title":"Medicine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hcs2.73","article-title":"Choices of medical institutions and associated factors in older patients with multimorbidity in stabilization period in China: A study based on logistic regression and decision tree model","volume":"2","author":"Wang","year":"2023","journal-title":"Health Care Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9662630","article-title":"Application of logistic regression and decision tree models in the prediction of activities of daily living in patients with stroke","volume":"2022","author":"Zhang","year":"2022","journal-title":"Neural Plast"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642253\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:12:56Z","timestamp":1758168776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642253\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":31,"alternative-id":["10.3389\/fonc.2025.1642253"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1642253","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1642253"}}